Immunologic influences on emotion regulation

Clinical Neuroscience Research

Volumn 4, Issue 5-6 SPEC. ISS., 2005, Pages 325-333

  Miller, Andrew H ^a   Capuron, Lucile ^a   Raison, Charles L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Cytokines; Depression; Fatigue; Immune system; Interferon alpha; Stress

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CYTOKINE; ETANERCEPT; INFLIXIMAB; PAROXETINE; PLACEBO;

ANOREXIA; ANXIETY; ARTICLE; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NEUROPATHY; BEHAVIORAL SCIENCE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DEPRESSION; DRUG MECHANISM; EMOTIONALITY; FATIGUE; FEAR; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; IRRITABILITY; LIFE EVENT; MENTAL DISEASE; MOOD; NEUROCHEMISTRY; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; SIDE EFFECT; SLEEP DISORDER; STRESS;

EID: 19944378444     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2005.03.010     Document Type: Article

References (79)

1. A.K. Abbas A.H. Lichtman Cellular and molecular immunology 2003 Saunders Philadelphia, PA
2. A. Miller B. Pearce C. Pariante Immune system and central nervous system interactions In: B. Sadock V. Sadock editors. Kaplan and Sadock's comprehensive textbook of psychiatry vol. 1 2000 Williams Philadelphia, CA 113-133
3. S.F. Maier L.R. Watkins Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition Psychol Rev 105 1998 83-107
4. A. Ericsson K.J. Kovacs P.E. Sawchenko A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons J Neurosci 14 1994 897-913
5. L.R. Watkins S.F. Maier L.E. Goehler Cytokine-to-brain communication: A review and analysis of alternative mechanisms Life Sci 57 1995 1011-1026
6. A.M. Van Dam J.G. Bol R.P. Gaykema et al. Vagotomy does not inhibit high dose lipopolysaccharide-induced interleukin-1beta immunoreactivity in rat brain and pituitary gland Neurosci Lett 285 2000 169-172
7. B. Schobitz E.R. De Kloet F. Holsboer Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain Prog Neurobiol 44 1994 397-432
8. S. Rivest S. Lacroix L. Vallieres S. Nadeau J. Zhang N. Laflamme How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli Proc Soc Exp Biol Med 223 2000 22-38
9. L.S. Brady A.B. Lynn M. Herkenham Z. Gottesfeld Systemic interleukin-1 induces early and late patterns of c-fos mRNA expression in brain J Neurosci 14 1994 4951-4964
10. W.A. Banks A.J. Kastin Blood to brain transport of interleukin links the immune and central nervous systems Life Sci 48 1991 PL117-PL121
11. W.A. Banks A.J. Kastin R.D. Broadwell Passage of cytokines across the blood-brain barrier Neuroimmunomodulation 2 1995 241-248
12. S.R. Plotkin W.A. Banks A.J. Kastin Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier J Neuroimmunol 67 1996 41-47
13. N. Quan E.L. Stern M.B. Whiteside M. Herkenham Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat J Neuroimmunol 93 1999 72-80
14. E.N. Benveniste Cytokine actions in the central nervous system Cytokine Growth Factor Rev 9 1998 259-275
15. N.J. Rothwell G. Luheshi S. Toulmond Cytokines and their receptors in the central nervous system: Physiology, pharmacology, and pathology J Vet Pharmacol Ther 69 1996 85-95
16. H.O. Besedovsky A. del Rey Immune-neuro-endocrine interactions: Facts and hypotheses Endocr Rev 17 1996 64-102
17. S. Gatti T. Bartfai Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: Comparison with interleukin-1 family and interleukin-6 Brain Res 624 1993 291-294
18. S. Laye P. Parnet E. Goujon R. Dantzer Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice Brain Res Mol Brain Res 27 1994 157-162
19. N. Quan S.K. Sundar J.M. Weiss Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide J Neuroimmunol 49 1994 125-134
20. B.L. Spangelo A.M. Judd R.M. MacLeod D.W. Goodman P.C. Isakson Endotoxin-induced release of interleukin-6 from rat medial basal hypothalami Endocrinology 127 1990 1779-1785
21. A.M. van Dam M. Brouns S. Louisse F. Berkenbosch Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: A pathway for the induction of non-specific symptoms of sickness? Brain Res 588 1992 291-296
22. S. Laye R.M. Bluthe S. Kent et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS Am J Physiol 268 1995 R1327-R1331
23. L.R. Watkins L.E. Goehler J.K. Relton et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for vagal mediation of immune-brain communication Neurosci Lett 183 1995 27-31
24. T. Hosoi Y. Okuma Y. Nomura Electrical stimulation of afferent vagus nerve induces IL-1beta expression in the brain and activates HPA axis Am J Physiol Heart Circ Physiol - Am J Physiol Regul Integr Comp Physiol 279 2000 R141-R147
25. A. Bierhaus J. Wolf M. Andrassy et al. A mechanism converting psychosocial stress into mononuclear cell activation Proc Natl Acad Sci USA 100 2003 1920-1925
26. K. Brebner S. Hayley R. Zacharko Z. Merali H. Anisman Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: Central monoamine, corticosterone, and behavioral variations Neuropsychopharmacology 22 2000 566-580
27. A.J. Dunn J. Wang Cytokine effects on CNS biogenic amines Neuroimmunomodulation 2 1995 319-328
28. A.J. Dunn J. Wang T. Ando Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress Adv Exp Med Biol 461 1999 117-127
29. A.J. Dunn A.H. Swiergiel The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment Neuroimmunomodulation 9 2001 163-169
30. S. Lacosta Z. Merali H. Anisman Central monoamine activity following acute and repeated systemic interleukin-2 administration Neuroimmunomodulation 8 2000 83-90
31. H. Shuto Y. Kataoka T. Horikawa N. Fujihara R. Oishi Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain Brain Res 747 1997 348-351
32. J.L. Jankowsky P.H. Patterson Cytokine and growth factor involvement in long-term potentiation. [republished from Mol Cell Neurosci 1999 Oct-Nov;14(4/5):273-86; PMID: 10588384] Mol Cell Neurosci 14 1999 273-286
33. C.L. Raison J.F. Gumnick A.H. Miller Neuroendocrine-immune interactions: implications for health and behavior In: D. Pfaff A. Arnold A. Etgen S. Fahrbach R.T. Rubin editors. Hormones, brain and behavior vol. 5 2002 Academic Press San Diego, CA 209-261
34. C. Rivier Influence of immune signals on the hypothalamic-pituitary axis of the rodent Front Neuroendocrinol 16 1995 151-182
35. M.J. Owens C.B. Nemeroff Physiology and pharmacology of corticotropin-releasing factor Pharmacol Rev 43 1991 425-473
36. M.N. Silverman A.H. Miller C.A. Biron B.D. Pearce Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection [see comment] Endocrinology 145 2004 3580-3589
37. Capuron L, Miller AH. Cytokines and psychopathology: Lessons from interferon-alpha. Biol Psychiatry 2004;56:819-24.
38. R. Dantzer Cytokine-induced sickness behavior: Where do we stand? Brain Behav Immun 15 2001 7-24
39. C.L. Raison A.H. Miller When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders Am J Psychiatry 160 2003 1554-1565
40. C.L. Raison A.H. Miller Depression in cancer: New developments regarding diagnosis and treatment Biol Psychiatry 54 2003 283-294
41. D.L. Evans J.P. Staab J.M. Petitto et al. Depression in the medical setting: Biopsychological interactions and treatment considerations J Clin Psychiatry 60 Suppl. 4 1999 40-45 [discussion 56]
42. J. Levine Y. Barak K.N. Chengappa A. Rapoport M. Rebey V. Barak Cerebrospinal cytokine levels in patients with acute depression Neuropsychobiology 40 1999 171-176
43. M. Maes Major depression and activation of the inflammatory response system Adv Exp Med Biol 461 1999 25-46
44. A. Sluzewska Indicators of immune activation in depressed patients Adv Exp Med Biol 461 1999 59-73
45. H. Besedovsky A. del Rey E. Sorkin C.A. Dinarello Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones Science 233 1986 652-654
46. C.M. Pariante A.H. Miller Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment Biol Psychiatry 49 2001 391-404
47. X. Wang H. Wu A.H. Miller Interleukin-1 alpha-induced activation of p38 mitogen-activated kinase inhibits glucocorticoid receptor function Mol Psychiatry 9 2004 65-75
48. M. Maes H.Y. Meltzer S. Scharpe et al. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression Psychiatry Res 49 1993 151-165
49. M. Maes S. Scharpe R. Verkerk et al. Seasonal variation in plasma l-tryptophan availability in healthy volunteers Relationships to violent suicide occurrence Arch Gen Psychiatry 52 1995 937-946
50. A.L. Mellor D.H. Munn Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? [see comments] Immunol Today 20 1999 469-473
51. C. Song A. Lin S. Bonaccorso et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression J Affect Disord 49 1998 211-219
52. L. Capuron A. Ravaud P.J. Neveu A.H. Miller M. Maes R. Dantzer Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy Mol Psychiatry 7 2002 468-473
53. L. Capuron G. Neurauter D.L. Musselman et al. Interferon-alpha-induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment Biol Psychiatry 54 2003 906-914
54. R.R. Brown Y. Ozaki S.P. Datta E.C. Borden P.M. Sondel D.G. Malone Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS Adv Exp Med Biol 294 1991 425-435
55. P. Moore H.P. Landolt E. Seifritz et al. Clinical and physiological consequences of rapid tryptophan depletion [see comments] Neuropsychopharmacology 23 2000 601-622
56. D.A. Papanicolaou Euthyroid sick syndrome and the role of cytokines Rev Endocr Metab Dis 1 2000 43-48
57. L. Capuron J.F. Gumnick D.L. Musselman et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions Neuropsychopharmacology 26 2002 643-652
58. M. Schaefer M.A. Engelbrecht O. Gut et al. Interferon alpha (IFNa) and psychiatric syndromes: A review Progress Neuro-Psychopharmacol Biol Psychiatry 26 2002 731-746
59. J.L. Taylor S.E. Grossberg The effects of interferon-alpha on the production and action of other cytokines Semin Oncol 25 1998 23-29
60. L. Capuron C.L. Raison D.L. Musselman D.H. Lawson C.B. Nemeroff A.H. Miller Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy Am J Psychiatry 160 2003 1342-1345
61. C.S. Cleeland T.R. Mendoza X.S. Wang et al. Assessing symptom distress in cancer patients: The MD Anderson symptom inventory Cancer 89 2000 1634-1646
62. G.R. Morrow J.T. Hickok J.A. Roscoe et al. Differential effects of paroxetine on fatigue and depression: A randomized double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program J Clin Oncol 21 2003 4635-4641
63. M.U. Goebel P.J. Mills M.R. Irwin M.G. Ziegler et al. Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: Differential effects and pathways Psychosom Med 62 2000 591-598
64. A. Heinz D. Hermann M.N. Smolka et al. Effects of acute psychological stress on adhesion molecules, interleukins and sex hormones: implications for coronary heart disease Psychopharmacology (Berlin) 165 2003 111-117
65. K.A. O'Connor J.D. Johnson M.K. Hansen et al. Peripheral and central proinflammatory cytokine response to a severe acute stressor Brain Res 991 2003 123-132
66. R.M. Barrientos E.A. Higgins D.B. Sprunger L.R. Watkins J.W. Rudy S.F. Maier Memory for context is impaired by a post context exposure injection of interleukin-1 beta into dorsal hippocampus Behav Brain Res 134 2002 291-298
67. R.M. Barrientos D.B. Sprunger S. Campeau et al. Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist Neuroscience 121 2003 847-853
68. E.D. Schmidt G. Aguilera R. Binnekade F.J. Tilders Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone-receptor mRNA in the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors Neuroscience 116 2003 275-283
69. R.M. Nesse Proximate and evolutionary studies of anxiety, stress and depression: Synergy at the interface Neurosci Biobehav Rev 23 1999 895-903
70. P.M. Ridker C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836-843
71. J.M. Fernandez-Real W. Ricart Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/ phenotype to thriftiness [see comments] Diabetologia 42 1999 1367-1374
72. W. Breitbart B. Rosenfeld M. Kaim J. Funesti-Esch A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease Arch Intern Med 161 2001 411-420
73. P.J. Goodnick R. Sandoval A. Brickman N.G. Klimas Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome Biol Psychiatry 32 1992 834-838
74. K.W. Rammohan J.H. Rosenberg D.J. Lynn A.M. Blumenfeld C.P. Pollak H.N. Nagaraja Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. [see comment] J Neurol Neurosurg Psychiatry 72 2002 179-183
75. N. Sarhill D. Walsh K.A. Nelson J. Homsi S. LeGrand M.P. Davis Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study Am J Hospice Palliative Care 18 2001 187-192
76. J.H. Vercoulen C.M. Swanink F.G. Zitman et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome Lancet 347 1996 858-861
77. U.A. Zifko M. Rupp S. Schwarz H.T. Zipko E.M. Maida Modafinil in treatment of fatigue in multiple sclerosis Results of an open-label study J Neurology 249 2002 983-987
78. G.R. Lichtenstein M. Bala C. Han K. DeWoody T. Schaible Infliximab improves quality of life in patients with Crohn's disease Inflamm Bowel Dis 8 2002 237-243
79. S.D. Mathias H.H. Colwell D.P. Miller L.W. Moreland M. Buatti L. Wanke Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo Clin Ther 22 2000 128-139